Ardelyx, Inc., a biopharmaceutical company, develops and sells medicines for the treatment of cardiorenal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program for the treatment of patients with hyperkalemia. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [05/21/2020 07:46 PDT] ARDX Expected to Trade Up Short Term
• [05/15/2020 07:40 PDT] ARDX Expected to Trade Down After Bearish Patterns Develop
• [05/14/2020 07:32 PDT] ARDX Expected to Trade Down After Bearish Patterns Develop
• [05/05/2020 12:23 PDT] ARDX SqueezeTrigger Price is $0.00. There is $0 That Short Sellers Still Need To Cover.
• [04/23/2020 11:07 PDT] ARDX SqueezeTrigger Price is $0.00. There is $0 That Short Sellers Still Need To Cover.
• [04/16/2020 08:13 PDT] ARDX Expected to Trade Up After Bullish Patterns Develop
• [04/08/2020 08:01 PDT] ARDX Expected to Trade Down After Bearish Patterns Develop